ILMN Illumina (ILMN) Q1 FY25 earnings call
Illumina delivered Q1 FY25 results at the high end of guidance, driven by strong NovaSeq X adoption and clinical market resilience. The company is navigating significant geopolitical and funding headwinds, particularly in China and US academic research, through strategic cost reductions and pricing actions. Management remains confident in its long-term strategy to achieve high single-digit revenue growth and margin expansion ex-China, while continuing to advance its multiomics innovation pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ILMN operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | This call Mar 2025 Q1 FY25 | Sep 2025 Q3 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|
| NovaSeq X placements | 91We placed 91 instruments during the quarter, bringing the installed base to 630.Source: earnings call transcript | 60+Our NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1, following more than 90 placements in Q4.Source: earnings call transcript | 55+In Q3, we had another strong quarter for the NovaSeq X with more than 55 instruments placed in line with our goal of 50 to 60 placements per quarter.Source: earnings call transcript | 95+Rest of World organic revenue grew 8.1%, above the high end of our guidance and demand for NovaSeq X remained high more than 3 years after launch with more than 95 placements in the quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.